LINC00511 enhances LUAD malignancy by upregulating GCNT3 via miR-195-5p

Youyi Zhang1†, Ping Xiao2† and Xiaobo Hu3*

Abstract

Background: Accumulating evidence suggests that LINC00511 acts as an oncogenic long non-coding RNA (lncRNA) in various cancers, including lung adenocarcinoma (LUAD). Hence, we attempted to elucidate the potential role of LINC00511 in LUAD.

Methods: LINC00511, miR-195-5p, and GCNT3 expression in LUAD was detected by qRT-PCR. Changes in the proliferation, migration, and invasion of LUAD cells after abnormal regulation of LINC00511, miR-195-5p, or GCNT3 were detected by CCK-8, BrdU, wound healing, and transwell assays. Bax and Bcl-2 protein expression was measured by western blotting. Additionally, we identified the targeting effects of LINC00511, miR-195-5p, and GCNT3 using luciferase and RNA immunoprecipitation (RIP) assays.

Results: LINC00511 and GCNT3 were found to be upregulated in LUAD, while miR-195-5p was downregulated. Silencing LINC00511 or GCNT3 decreased the proliferation, migration, invasion, and Bcl-2 protein content in LUAD cells and increased the expression of Bax. Interference with miR-195-5p promoted malignant proliferation of cancer cells. miR-195-5p expression was affected by LINC00511 and targeted GCNT3.

Conclusion: Silencing LINC00511 promotes GCNT3 expression by inhibiting miR-195-5p and ultimately stimulates the malignant progression of LUAD.

Keywords: LINC00511, miR-195-5p, GCNT3, LUAD

Introduction

Lung adenocarcinoma (LUAD) is the most common subtype of lung cancer with the highest mortality, accounting for nearly 40% of all lung cancer cases [1, 2]. Despite remarkable achievements in the exploration and treatment of LUAD pathogenesis, morbidity and mortality have increased worldwide in recent years due to its high resistance to conventional radiotherapy and chemotherapy. Moreover, the overall survival rate of LUAD patients is less than 5 years [3, 4]. Therefore, understanding the molecular pathways driving LUAD progression and its associated targets is urgently needed.

Long non-coding RNAs (lncRNAs) are RNA molecules exceeding 200 nucleotides in length, and are emerging as crucial players in the progression of different diseases [5]. Abnormally expressed lncRNAs play carcinogenic or anticancer roles during the development of malignant tumors. It has been reported that lncRNAs mediate many tumor-related mechanisms such as transcriptional and translational regulation, protein modification, and RNA-protein or protein-protein complex formation [6]. The mRNA-miRNA-lncRNA-competing endogenous RNA network can be used as a biomarker for the prognosis of various human cancers [7]. For instance, the lncRNA HOTAIR enhances breast cancer cell growth and metastasis by negatively regulating miR-20a-5p and positively regulating HMGA2 [8]. LINC01133 inhibits
the occurrence and metastasis of gastric cancer through the regulation of adenomatous polyposis coli (APC) gene expression and the Wnt-β-catenin pathway by competitive adsorption of miR-106a-3p, and is associated with good prognosis in gastric cancer patients [9]. A growing number of studies have shown that lncRNAs are significantly involved in LUAD. For example, lncRNA HOXA11-As, as a competitive endogenous RNA (ceRNA), promotes cisplatin resistance in LUAD cells through miR-454-3p/STAT3, and predicts a shorter survival time for LUAD patients with high expression of this lncRNA [10]. Moreover, LINC00511 has been shown to be overexpressed in LUAD and inhibits cell proliferation and tumorigenesis [11]. It has been suggested that understanding the functional mechanism of LINC00511 in LUAD may be helpful in developing new and effective molecular markers for this disease.

MicroRNAs (miRNAs) negatively regulate post-transcriptional gene expression, thereby modulating metastasis and carcinogenesis by altering the expression of tumor suppressors or oncogenes [12, 13]. miR-195-5p is a well-studied miRNA. In recent years, several studies have revealed that miR-195-5p plays a tumor-suppressive role in lung cancer by inhibiting the biological functions of glycolysis and proliferation of cells, thus indicating a good prognosis of lung cancer patients [14, 15]. Glucosaminyl (N-acetyl) transferase 3, mucin type (GCNT3), is a novel core mucin synthase [16] that plays a role as a cancer-promoting factor in gastric [16], colon [17], ovarian [18], and lung [19] cancers. However, there are few reports on the function of LINC00511/miR-195-5p/GCNT3 axis in LUAD.

This study demonstrated that LINC00511 plays a crucial role in LUAD and analyzed the effects of different LINC00511/miR-195-5p/GCNT3 regulatory strategies on LUAD cell function. This widens the field of vision for molecular targets and therapeutic strategies for LUAD.

Materials and Methods

Human tissues and cell culture

A total of 40 pairs of LUAD tissues and adjacent cancer-free tissues were collected from LUAD patients treated in our hospital. The study was approved by the Ethics Committee of our hospital, and all the subjects signed the informed consent form. Two independent oncologists estimated the staging of the disease according to the 8th edition of the TNM classification for lung cancer [20]. Patients were classified as follows: 8 cases of stage I, 17 cases of stage II, 11 cases of stage III, and 3 cases of stage IV. All surgically resected samples were immediately transferred to liquid nitrogen and stored at −80 °C until further analysis.

A549, Calu-3 (human LUAD cells), and BEAS-2B (human bronchial epithelial cells) were purchased from ATCC (USA) and cultured in DMEM (HyClone, USA). The human LUAD cell lines DV-90 and PC-9 were purchased from Cobioer (China) and cultured in RPMI-1640 medium (HyClone). All media were supplemented with 10% FBS (HyClone), 100 mg/mL streptomycin (Gibco, USA) and 100 U/mL penicillin (Gibco). All cell lines were incubated at 37 °C with 5% CO2.

qRT-PCR assay

Total miRNA was extracted using the mirVanaTM miRNA isolation kit (Ambion, USA). cDNA was synthesized from total RNA using miRNA-specific primers and the TaqMan miRNA reverse transcription kit (ABI, USA) according to the manufacturer’s instructions. Sequence-specific primers were used for PCR amplification performed on the Applied Biosystems 7500 real-time PCR system (Applied Biosystems, USA). U6 was used as a control to normalize miR-195-5p expression. Data were evaluated using the 2^ΔΔCt method.

Total RNA was extracted using the RNA high-purity total RNA rapid extraction kit (Qiagen, Japan). The isolated total RNA was reverse transcribed using the PrimeScript RT reagent kit (TaKaRa, Japan). The mRNA expression levels of LINC00511 and GCNT3 were detected using the SYBR Premix Ex Taq II kit (TaKaRa). GAPDH was used as the internal reference control. The primers used are listed in Table 1.

Cell transfection

Specific siRNAs targeting LINC00511 (si-LNC), and GCNT3 (si-GCNT3), and control siRNA plasmid (si-NC) were synthesized by RiboBio (Guangzhou, China). The miR-195-5p mimic, miR-195-5p inhibitor, and the corresponding controls (mimic-NC, inhibitor-NC) were purchased from Switchgear Genomics (USA). PC9 and

Table 1 The PCR primers used in the presence work

| Gene         | Primer sequence (5’-3’) |
|--------------|------------------------|
| LINC00511    | Forward: CTACAAGAGGGTAAGTGTCAG  |
|              | Reverse: AAGTGCACCCCCCATCGTAC |
| miR-195-5p   | Forward: GGGGTAGGAGGCAGAGAAAAT |
|              | Reverse: TCCATGGCCTGCTGG |
| GCNT3        | Forward: GCCAGTAAGCTGCTGTCGG |
|              | Reverse: GCCAGTAAGCTGCTGTCGG |
| GAPDH        | Forward: GACAGTCAGCCGGATCTTCT |
|              | Reverse: TAAAGAACAGCCGCTGGTAC |
| U6           | Forward: CACCCAGAGTCCTCCTCCTCAGTG |
|              | Reverse: GCTGAGAGGGGTCACAGCT |
A549 cells were transfected with 50 nM si-LNC, 50 nM si-GCNT3, 100 nM miR-195-5p mimic, and 75 nM miR-195-5p inhibitor using Lipofectamine 2000 (Invitrogen, USA) according to the manufacturer’s instructions. After 48 h of transfection, qRT-PCR was performed to detect the transfection efficiency.

**Western blotting**

Total proteins were isolated using RIPA lysis buffer (Thermo Fisher Scientific, Waltham, MA, USA) and quantified using the BCA protein analysis kit (Pierce, USA). Proteins were separated on a 10% gel by SDS-PAGE, and subsequently transferred onto PVDF membranes. The membranes were blocked with 5% skim milk at 25 °C for 1 h, and then incubated with primary antibodies, Bax (ab32503; Abcam, UK), Bcl-2 (ab32124; Abcam), GCNT3 (ab77728; Abcam), and GAPDH (ab8245; Abcam) overnight at 4 °C. After washing with PBST buffer (containing 0.1% Tween-20), the membranes were incubated with secondary antibodies (ab6721; Abcam) for 1 h at 25 °C. ECL substrates (Millipore, USA) were used for target protein detection, and ImageJ software was used for standard protein analysis.

**CCK-8 assay**

PC9 and A549 cells were seeded into 96-well plates at a density of $1 \times 10^4$ cells/well. After incubation for 0, 24, 48, or 72 h, CCK-8 solution (10 μL) (Dojindo Molecular Technologies, Japan) was added into each well. After 2 h of further incubation, a microplate reader (BioTek Instruments, USA) was used to measure the optical density (OD450) at each indicated time point.

**BrdU assay**

DNA synthesis was measured by BrdU incorporation into PC9 and A549 cells to determine cell proliferation. PC9 and A549 cells (2 $\times 10^3$ cells/well) were seeded in a 96-well culture plate. After 48 h of culture, 10 μM BrdU (BD Pharmingen, USA) was added and the cells were incubated for another 2 h. The medium was removed and co-cultured with BrdU antibody (Sigma-Aldrich) for 60 min, followed by incubation with tetramethylbenzidine (peroxidase substrate) for 30 min. The absorbance of each well was determined at 450 nm.

**Wound healing assay**

PC9 and A549 cells were collected and seeded in 6-well plates after transfection for 48 h. When the cells reached 90% confluency, the monolayer cell surface was scratched with a sterile 200 μL pipette tip. After washing with PBS, the cells were cultured in serum-free medium. Wound images were observed at the specified time points (0 h and 24 h). The scratch width (W) was determined, and the cell migration rate was calculated as (W0 h-W24 h)/W0 h $\times$ 100% [21].

**Transwell assay**

Transwell chambers (Corning, NY, USA) pre-coated with 20 μg of Matrigel (Corning, NY, USA) were used to perform this assay. The cells were suspended in serum-free medium and then placed in the upper chamber, and the medium containing 10% FBS was placed in the lower chamber. The cells in the upper chamber were gently wiped off after incubation for 48 h. Cells in the lower chamber were fixed with methanol and stained with 0.1% crystal violet at 25°C. Images were captured by a microscope (Olympus, Japan) to count the number of cells.

**Luciferase assay**

Luciferase reporter plasmids, including wild-type and mutant pGLO-LINC00511 (LINC00511-WT and LINC00511-MUT), and wild-type and mutant pGLO-GCNT3 3’UTR (GCNT3-WT and GCNT3-MUT) were constructed by Sangon (China). The reporter plasmids were co-transfected with mimic-NC or miR-195-5p mimic into PC9 and A549 cells using Lipofectamine 2000. After 48 h of transfection, luciferase activity was detected using the dual-luciferase reporter kit (Promega, USA).

**RNA Immunoprecipitation (RIP) assay**

The RIP RNA-binding protein immunoprecipitation kit (Millipore) was used for this analysis. Briefly, PC9 and A549 cells transfected with mimic-NC or miR-195-5p mimic were lysed and incubated with RIP buffer containing magnetic beads bound to Ago2 antibody or IgG (Millipore). LINC00511 expression was detected by qRT-PCR.

**Statistical analysis**

The data were expressed as the mean ± SD and analyzed using GraphPad Prism (GraphPad, USA). Statistical
Fig. 1 (See legend on previous page.)
differences between multiple groups were analyzed using one-way ANOVA. Student’s t-test was used for paired comparison. Statistical significance was set at P < 0.05.

**Results**

**LINC00511/miR-195-5p/GCNT3 axis is a potential regulator of lung cancer via a ceRNA network**

By examining the differentially expressed lncRNAs in both LUAD and lung squamous cell carcinoma (LUSC) samples compared with normal non-tumor samples with adjusted P < 0.05, and logFC>1.5, we identified three candidates by Gene Expression Profiling Interactive Analysis (GEPIA2) 2. In descending order of expression, these were LINC00511, FAM83H-AS1, and ZFPM2-AS1 (Fig. 1A). LINC00511 was the most significantly upregulated lncRNA and has been reported to be a significant driver of lung cancer [22–26]. In addition, we analyzed the gene expression profile of GSE85841 that included eight LUAD samples and adjacent non-tumor samples with adjusted P<0.05 and logFC>1.5, and researched the top five most significantly upregulated genes: SFRP5, CST2, SPP1, GCNT3, and NHLRC1 (Fig. 1B). According to the GEPIA database, SFRP5 expression did not differ between LUAD, LUSC, and non-tumor tissues (Fig. 1C). CST2 expression differed only between LUAD and non-tumor tissues (Fig. 1D), and NHLRC1 expression differed between LUSC and non-tumor tissues (Fig. 1G). SPP1 and GCNT3 were differentially expressed between LUAD or LUSC and non-tumor controls (Fig. 1E, F). While SPP1 has been studied extensively in lung cancer [27–30], GCNT3 has not been well-studied. Knockdown of GCNT3 has been reported to suppress lung cancer cell proliferation and mobility [19]. To seek the miRNA connecting LINC00511 and GCNT3, StarBase v.2.0 was used to predict the miRNAs binding to LINC00511 and GCNT3. Using Venny 2.1.0, it was found that four

![Fig. 2](image-url)

**Fig. 2** LINC00511 was upregulated in LUAD. **A** The expression of LINC00511 was detected by qRT-PCR assay in Human LUAD cell line (A549, Calu-3, DV-90 and PC-9) and human bronchial epithelial cell line BEAS-2B. **B** The expression of LINC00511 was detected by qRT-PCR assay in cancer tissues (n=40) and normal tissues (n=40). **C** The subcellular localization assay for LINC00511. **D** The expression of LINC00511 was tested by qRT-PCR in A549 and PC-9 cells transfected with si-NC and si-lnc for 48h. **P<0.001 compared with si-NC. si-lnc, siRNA of LINC00511. si-NC, negative control of si-RNA.
Fig. 3  Interference with LINC00511 inhibited the malignant proliferation of LUAD cells. A Cell viability was detected by CCK-8 assay in A549 and PC9 cells transfected with si-NC and si-lnc for 0, 24, 48 or 72 h. B Cell proliferation was determined by BrdU assay in A549 and PC9 cells transfected with si-NC and si-lnc for 48 h. C Bax and Bcl-2 protein expression detected by western blot assay in A549 and PC9 cells transfected with si-NC and si-lnc for 48 h. D Migration capacity was determined by wound healing assay in A549 and PC9 cells transfected with si-NC and si-lnc for 48 h. E Cell invasion ability was detected by transwell invasion assay in A549 and PC9 cells transfected with si-NC and si-lnc for 48 h. **P < 0.001 compared with si-NC. si-lnc, siRNA of LINC00511. si-NC, negative control of si-RNA.
miRNAs were associated with LINC00511 and GCNT3: miR-15a-5p, miR-15b-5p, miR-16-5p, and miR-195-5p (Fig. 1H). miR-195-5p has been reported to be a tumor suppressor in lung cancer [14, 31–34]. Therefore, we were interested in examining whether miR-195-5p links LINC00511 and GCNT3, thus exerting cancer-suppressing functions in lung cancer.

LINC00511 is upregulated in LUAD
LINC00511 has been identified as a lncRNA overexpressed in various cancers. Therefore, we explored the changes in LINC00511 expression in LUAD cells. At the cellular level, LINC00511 expression was found to be elevated in A549, Calu-3, DV-90, and PC9 cell lines compared with BEAS-2B cells, and the expression levels of LINC00511 were higher in A549 and PC9 cells (Fig. 2A). At the clinical level, the results revealed an approximately 3-fold increase in LINC00511 expression in LUAD tissues compared to normal tissues (Fig. 2B). In addition, the subcellular localization of LINC00511 was investigated. The data revealed that LINC00511 was abundant in the cytoplasm, indicating that it mainly functions in the cytoplasm (Fig. 2C). Furthermore, transfecting A549 and PC9 cells with LINC00511 specific siRNA showed a 60% decrease in LINC00511 expression levels in the si-LNC group compared to that in the si-NC group (Fig. 2D).

Interference with LINC00511 inhibited the malignant proliferation of LUAD cells
Next, we investigated the effect of LINC00511 on the biological functions of LUAD cells. The CCK-8 assay indicated that the viability of A549 and PC9 cells decreased to approximately 40% compared to that of the si-NC group after knockdown of LINC00511 (Fig. 3A). The BrdU assay showed that in comparison with the si-NC group, cell proliferation in the si-LNC group decreased by more than 30% (Fig. 3B). Western blotting revealed that interference with LINC00511 increased Bax protein levels in A549 and PC9 cells by 1.9-fold and 1.5-fold, respectively, and reduced Bcl-2 protein levels by 40 and 35%, respectively (Fig. 3C). In addition, the effects of LINC00511 on the metastasis of A549 and PC9 cells were monitored. The wound healing assay revealed that silencing LINC00511 reduced cell migration rates by more than 30% (Fig. 3D). Moreover, the transwell assay showed a 60% reduction in cell invasion in the si-LNC group compared to the si-NC group (Fig. 3E). These results suggested that low LINC00511 expression inhibited the malignant proliferation of LUAD cells.

LINC00511 targeted and negatively regulated miR-195-5p
Next, the miRNA regulated by LINC00511 was identified. The Starbase website showed that LINC00511 contained a binding site for miR-195-5p (Fig. 4A). In addition, wild-type or mutant LINC00511 and miR-195-5p mimic were transfected into A549 and PC9 cells. It was found that the luciferase activity of cells transfected with LINC00511-WT and miR-195-5p mimic decreased by more than 50%, and the luciferase activity of cells transfected with LINC00511-MUT and miR-195-5p mimic did not change significantly (Fig. 4B). Additionally, the RIP assay showed that in A549 and PC9 cells transfected with miR-195-5p mimic, the expression of LINC00511 increased approximately 15 times after Ago2 treatment, compared to IgG (Fig. 4C). Next, in clinical samples, it was found that miR-195-5p expression in cancer tissues decreased by 70% (Fig. 4D). Pearson analysis revealed that LINC00511 was negatively correlated with miR-195-5p expression in cancer tissues (Fig. 4E). Further detection by qRT-PCR showed that miR-195-5p levels in A549 and PC9 cells were lower than that in BEAS-2B cells (Fig. 4F). Additionally, it was found that knockdown of LINC00511 expression upregulated miR-195-5p levels in A549 and PC9 cells, and silencing miR-195-5p downregulated miR-195-5p levels, and reversed the effect of LINC00511 knockdown on miR-195-5p levels (Fig. 4G).

LINC00511 negatively regulated miR-195-5p to affect the malignant proliferation of LUAD cells
Next, the functional changes in A549 and PC9 cells induced by LINC00511 or miR-195-5p were studied. As shown in Fig. 5A, low expression of miR-195-5p facilitated the survival of A549 and PC9 cells by approximately 1.3 times. When both LINC00511 and miR-195-5p
Fig. 4  (See legend on previous page.)

A LINC00511: 5' GAAAGUGUUUCCUCUCUGCUA 3'
miR-195-5p: 3' CGGUUAUAAA - GACACGACGAU 5'

B Relative luciferase activity
-PC9
- A549
- LINC00511
- LINC00511
- WT
- MUT

C Relative LINC00511 expression
-PC9
- A549
- mimic-NC
- mimic
- Ago2
- IgG

D Relative miR-195-5p expression
- Normal
- Tumor

E Relative LINC00511 expression
- BEAS-2B
- PC9
- A549

F Relative miR-195-5p expression
- BEAS-2B
- PC9
- A549

G Relative expression
- LINC00511
- miR-195-5p

Legend:
- Si-NC
- inhibitor-NC
- Si-Inc
- inhibitor
- Si-Inc+inhibitor

Y = -5.563X + 5.372
R² = 0.5241
P < 0.0001
were expressed at low levels, cell viability was restored (Fig. 5A). In addition, the BrdU assay revealed that interference with miR-195-5p augmented the proliferation of LUAD cells and eliminated the inhibitory effect of silencing LINC00511 (Fig. 5B). Western blot analysis showed that Bax protein levels were more than 50% lower in the inhibitor group than in the inhibitor-NC or si-LNC + inhibitor groups, and Bcl-2 protein levels were increased by more than 1.5 times (Fig. 5C). Moreover, both A549 and PC9 cells exhibited higher migration rates after miR-195-5p knockdown compared to the inhibitor-NC group or si-LNC + inhibitor group (Fig. 6A).

The transwell assay indicated that low expression of miR-195-5p facilitated cell invasion by approximately 1.5-fold, thereby preventing the effect of low expression of LINC00511 on cell invasion (Fig. 6B). These results revealed that silencing miR-195-5p reversed the functional effects of LINC00511 in A549 and PC9 cells.

**GCNT3 is the target gene of miR-195-5p**

The StarBase website showed that GCNT3 contained two binding sites for miR-195-5p (Fig. 7A). The luciferase activity of A549 and PC9 cells co-transfected with GCNT3-WT and miR-195-5p
Fig. 6 LINC00511 negatively regulated miR-195-5p to affect the metastasis of LUAD cells. A Migration capacity was determined by wound healing assay in A549 and PC9 cells transfected with si-lnc or inhibitor for 48h. B Cell invasion ability was detected by transwell invasion assay in A549 and PC9 cells transfected with si-lnc or inhibitor for 48h. *P < 0.05, **P < 0.001 compared with si-NC group. $$$P < 0.001 compared with inhibitor-NC. #P < 0.05, ##P < 0.001 compared with si-lnc + inhibitor. si-lnc, siRNA of LINC00511. si-NC, negative control of siRNA. inhibitor, miR-195-5p inhibitor. inhibitor-NC, negative control of inhibitor. si-lnc + inhibitor, siRNA of LINC00511 + miR-195-5p inhibitor.

Fig. 7 GCNT3 was the target gene of miR-195-5p.
A The schematic diagram presents the complementary binding sites within GCNT3 and miR-195-5p. B Luciferase reporter assay confirmed the molecular binding. **P < 0.001 compared with WT + NC. #P < 0.05 compared with WT + mimic. C The expression of GCNT3 was detected by qRT-PCR assay in cancer tissues and normal tissues. **P < 0.001. D Pearson analysis was used to analyze the expression of GCNT3 and miR-195-5p in cancer tissues. E The expression of GCNT3 was detected by qRT-PCR assay in A549, PC9 and BEAS-2B cells. **P < 0.001 compared with BEAS-2B. F The GCNT3 mRNA expression were detected by qRT-PCR assay in A549 and PC9 cells transfected with si-lnc for 48h. G The GCNT3 protein expression were detected by western blot assay in A549 and PC9 cells transfected with si-lnc for 48h. H The GCNT3 protein expression were detected by western blot assay in A549 and PC9 cells transfected with si-GCNT3 or inhibitor for 48h. **P < 0.001 compared with si-NC group. $$$P < 0.001 compared with inhibitor-NC. ##P < 0.001 compared with si-GCNT3 + inhibitor. si-GCNT3, siRNA of GCNT3. si-NC, negative control of siRNA. inhibitor, miR-195-5p inhibitor. inhibitor-NC, negative control of inhibitor. si-GCNT3 + inhibitor, siRNA of GCNT3 + miR-195-5p inhibitor.
Fig. 7 (See legend on previous page.)
mimic decreased by more than 50%, and that of cells co-transfected with MUT1 and miR-195-5p mimic decreased by approximately 40%, and cells co-transfected with MUT2 and miR-195-5p mimic showed a 25% decrease in luciferase activity (Fig. 7B). It was observed that miR-195-5p binds to the 3′-UTR of GCNT3. qRT-PCR showed that GCNT3 levels were nearly 3 times higher in cancer tissues than in normal tissues (Fig. 7C). Additionally, there was an inverse correlation between GCNT3 and miR-195-5p in cancer (Fig. 7D). GCNT3 levels in A549 and PC9 cells were approximately 3 times higher than in BEAS-2B cells (Fig. 7E). Moreover, we investigated the regulatory effect of LINC00511 on GCNT3. qRT-PCR and western blot showed that the mRNA and protein levels of GCNT3 decreased by about 70% and 50% respectively in the si-lnc group compared with the si-NC group (Fig. 7F and G). Indicating that LINC00511 positively regulate the expression of GCNT3. In addition, GCNT3-specific siRNA and miR-195-5p inhibitor were transfected into A549 and PC9 cells. The GCNT3 protein expression increased after miR-195-5p downregulation, which was reduced after GCNT3 downregulation, which eliminated the
impact of miR-195-5p downregulation on GCNT3 protein expression (Fig. 7H).

**GCNT3 silencing reversed the effect of miR-195-5p inhibitor on the malignant proliferation of LUAD cells**

Next, we verified whether the effects of miR-195-5p on the biological function of LUAD cells depends on GCNT3 expression. The CCK-8 assay showed that interference with GCNT3 significantly reduced cell viability, while reversing the survival-promoting effect of miR-195-5p inhibitor (Fig. 8A). The BrdU assay confirmed that compared with the si-NC or si-GCNT3 + inhibitor groups, the cell proliferation levels of the si-GCNT3 group decreased by more than 40% (Fig. 8B). Western blotting showed that silencing GCNT3 increased Bax protein levels by more than 1.5-fold in A549 and PC9 cells, reduced Bcl-2 protein levels by more than 40%, and rescued apoptosis induced by miR-195-5p inhibitor (Fig. 8C). In addition, the wound healing assay indicated that interference with GCNT3 decreased the cell migration rate and eliminated the effect of miR-195-5p interference (Fig. 9A). The transwell assay was performed to detect cell invasion. Low expression of GCNT3 reduced the invasion levels of A549 and PC9 cells to approximately 40% compared to
that of the si-NC group, as well as eliminated the cell invasion induced upon treatment with miR-195-5p inhibitor (Fig. 9B).

**Discussion**

Numerous studies have revealed that LINC00511 is a multipotent cancer promoter. LINC00511 is linked with poor prognosis in breast cancer patients and facilitates the growth of cancer stem cells and tumors [35]. LINC00511 enhances proliferation, migration, and invasion, as well as restrains apoptosis of gastric and cervical cancer cells [36, 37]. In this study, we found that LINC00511 was overexpressed in LUAD, which is consistent with the results reported by Wei et al. [11]. Additionally, this study further revealed the regulation of LINC00511 on the biological function of LUAD cells, and found that LINC00511 induced the proliferation, migration, and invasion of LUAD cells and inhibited apoptosis. This finding is also consistent with observations in gastric cancer [36] and cervical cancer [37]. This suggests that LINC00511 may be a tumor-promoting factor in LUAD.

Accumulated literature indicates that miR-195-5p serves as a tumor-inhibiting factor in a variety of cancers, including colorectal cancer [38], breast cancer [39], and cervical cancer [40]. Moreover, Long et al. [33] found that miR-195-5p was downregulated in lung cancer, inhibiting the survival and metastasis of cells. Xin et al. [34] also revealed a decrease in miR-195-5p expression in LUAD, which inhibits malignant cell proliferation. In this study, it was revealed that silencing miR-195-5p had a positive regulatory effect on the proliferation, migration, and invasion of LUAD cells, and a negative regulatory effect on apoptosis, which is in agreement with the results of previous studies. In addition, bioinformatics analysis, luciferase assay, and RIP analysis indicated that miR-195-5p was mediated by LINC00511, which was consistent with the observation that miR-195-5p binds to LINC00511 as reported by Li et al. [41].

Previous studies found that GCNT3 was significantly correlated with clinicopathological malignant phenotype and poor overall survival of lung cancer patients, and GCNT3 knockdown inhibited epithelial mesenchymal transformation, invasion, migration, and proliferation ability of lung cancer cells [19]. Clinically, this study also showed an increase in GCNT3 levels in LUAD. Functional analysis also showed that downregulating the expression of GCNT3 could attenuate the proliferation, migration, and invasion of LUAD cells. In addition, further exploration showed that GCNT3 was a target gene of miR-195-5p and was involved in altering the function of miR-195-5p in LAUD cells. Taken together, these analyses revealed that GCNT3 was regulated by LINC00511/miR-195-5p to maintain the malignant proliferation of LAUD cells.

However, it is not sufficient to demonstrate the impact of LINC00511/miR-195-5p/GCNT3 in LUAD at the cellular level. Elucidating the mechanism by which LINC00511 affects the metastasis of cancer cells in vivo is of great value to further understand the progression of LUAD. In addition, analysis of the correlation of pathological phenotypes in a larger sample size is the focus of future research.

**Conclusions**

In conclusion, we elucidated that miR-195-5p binds to LINC00511 and regulates the target gene GCNT3 in LUAD. These data indicate a molecular pathway mediated by LINC00511 in the progression of LUAD. In addition, miR-195-5p/GCNT3 acts as a potential target for LINC00511 and is of great significance in the diagnosis and treatment of LUAD.

**Abbreviations**

cRNA: competitive endogenous RNA; lncRNA: long non-coding RNA; LUAD: lung adenocarcinoma; miRNAs: microRNAs.

**Supplementary Information**
The online version contains supplementary material available at https://doi.org/10.1186/s12885-022-09459-7.

**Acknowledgements**
None.

**Authors’ contributions**
YZ designed the study. PX performed most of the experiments. XH collected the data and wrote the paper. All authors read and approved the final manuscript.

**Funding**
No funding was received.

**Availability of data and materials**
All data generated or analysed during this study can be found in below websites. One miRNA microarrays (GSE85841) from GEO DataSets (https://www.ncbi.nlm.nih.gov/geo/) were used to screen the upregulated genes. The expression of the 5 genes in LUAD and LUSC. Data obtained from GEPIA database (http://geopia.cancer-pku.cn/). starBase (http://starbase.info/) was used to predict the binding sites.

**Declarations**

**Ethics approval and consent to participate**
The present study was approved by the Ethics Committee of Sichuan Academy of Medical Sciences, Sichuan Provincial People’s Hospital (Chengdu, China). The processing of clinical tissue samples is in strict compliance with the ethical standards of the Declaration of Helsinki. All patients signed written informed consent.

**Consent for publication**
All patients signed written informed consent.
Competing interests
The authors declare that there is no conflict of interests.

Author details
1 Department of Radiology, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, Chengdu 610072, Sichuan, China. 2 Department of Thoracic Surgery, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610041, Sichuan, China. 3 Department of Respiratory Diseases, Chengdu First People's Hospital, No. 18, North Wangxiang Road, Gaoxin District, Chengdu 610016, Sichuan, China.

Received: 25 May 2021 Accepted: 8 March 2022
Published online: 10 April 2022

References
1. Hutchinson BD, Shroff GS, Truong MT, Ko JP. Spectrum of Lung Adenocarcinoma. Semin Ultrasound CT MR. 2019;40(3):55–64.
2. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger K, Yatabe Y, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. Proc Am Thorac Soc. 2011;8(5):381–5.
3. Costa GI, de Mello MJG, Ferreira CG, Bergmann A, Thuler LCS. Increased proliferation and migration in EBV-associated gastric cancer. Virology. 2018;517:179–90.
4. Denisenko TV, Budkevich IN, Zhivotovsky B. Cell death-based treatment by Sponging miR-195-5p and Increasing Glucose Transporter Member 3 by Directly Targeting CIAPIN1. Pathol Oncol Res. 2019;25(3):1181–90.
5. Schmitz SU, Grote P, Herrmann BG. Mechanisms of long noncoding RNA function in development and disease. Cell Mol Life Sci. 2016;73(13):2491–509.
6. Peng WX, Koirala P, Mo YY. LncRNA-mediated regulation of cell signaling in cancer. Oncogene. 2017;36(41):5661–7.
7. Wang W, Lou W, Ding B, Yang B, Lu H, Kong Q, et al. A novel miRNA-miRNA-lncRNA competing endogenous RNA triple sub-network associated with prognosis of pancreatic cancer. Aging. 2019;11(9):2610–27.
8. Zhao W, Geng D, Li S, Chen Z, Sun M. LncRNA HOAIR influences cell growth, migration, invasion, and apoptosis via the miR-20a-3p/HMG2 axis in breast cancer. Cancer Med. 2018;7(3):842–55.
9. Yang XZ, Cheng TT, He QI, Lei ZY, Chi J, Yang Z, et al. LINC00511 as a circulating miRNA interacts with its target PTEN in gastric cancer. Cell Death Dis. 2018;9(2):117.
10. Li D, Zhang J, Li J. Role of miRNA sponges in hepatocellular carcinoma. Cell Death Disc. 2018;8:1021.
11. Wei Y, Zhang X. Transcripome analysis of distinct long non-coding RNA transcriptional fingerprints in lung adenocarcinoma and squamous cell carcinoma. Tumour Biol. 2016;37(6):16275–85.
12. Lee YS, Dutta A. MicroRNAs in cancer. Annu Rev Pathol. 2009;4:199–227.
13. Li D, Zhang J, Li J. Role of miRNA sponges in hepatocellular carcinoma. Clin Chim Acta. 2020;500:10–9.
14. Zheng J, Xu T, Chen F, Zhang Y. MiRNA-195-5p Functions as a Tumor Suppressor in Hepatocellular Carcinoma. Mol Cancer. 2012;11:569–78.
15. Liu J, Zhang Y, Liu W, Zhang Q, Xiao H, Song H, et al. MiR-BART1-5p targets core 2β-1,6-acetylgalactosaminyltransferase GCNT3 to inhibit cell proliferation and migration in EBV-associated gastric cancer. Virology. 2020;541:63–74.
16. González-Vallinas M, Molina S, Vicente G, Zarza V, Martín-Hernández R, García-Risco MR, et al. Expression of microRNA-15b and the glycosyltransferase GCNT3 correlates with antitumor efficacy of Rosemary diterpenes in colon and pancreatic cancer. PLoS One. 2014;9(6):e98556.
17. Fernández LP, Sánchez-Martínez R, Vargas T, Hernanz J, Martín-Hernández R, Mendiola M, et al. The role of glycosyltransferase enzyme GCNT3 in colon and ovarian cancer prognosis and chemoresistance. Sci Rep. 2018;8(1):8485.
18. Li Q, Ran P, Zhang X, Guo X, Yuan Y, Dong T, et al. Downregulation of N-Acetylglucosaminyltransferase GCNT3 by miR-302b-3p Decreases Non-Small Cell Lung Cancer (NSCLC) Cell Proliferation, Migration and Invasion. Cell Physiol Biochem. 2018;50(3):967–70.
19. Eberhardt WE, Mitchell A, Crowley J, Kond H, Kim YT, Turrisi A 3rd, et al. The IASLC Lung Cancer Staging Project: Proposals for the Revision of the M Descriptors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer. J Thorac Oncol. 2015;10(11):1515–22.
20. Grifffen TL, Dammer EB, Dill CD, Carey KM, Young CD, Núñez SK, et al. Multivariate transcriptome analysis identifies networks and key drivers of chronic lymphocytic leukemia relapse risk and patient survival. BMC Med Genet. 2021;14(1):171.
21. Zhu FY, Zhang SR, Wang LH, Wu WD, Zhao H. LINC00511 promotes the progression of non-small cell lung cancer through downregulating LATS2 and KLF2 by binding to EZH2 and LSD1. Eur Rev Med Pharmacol Sci. 2019;23(19):8377–90.
22. Jiang L, Xie X, Dang F, Mei J, R. Silencing LINC00511 inhibits cell proliferation, migration, and epithelial-mesenchymal transition via the PTEN-AKT-FOXO1 signaling pathway in lung cancer. Biochem Cell Biol. 2021;99(2):276.
23. Wu Y, Li L, Wang Q, Zang L, He C, Wang X, et al. LINC00511 promotes lung squamous cell carcinoma proliferation and migration via inhibiting miR-150-5p and activating TADA1. Transl Lung Cancer Res. 2020;9(4):1138–48.
24. Sun CC, Li SJ, Li G, Hua RX, Zhou XH, Li DJ. Long Intergenic Noncoding RNA 00511 Acts as an Oncogene in Non-small-cell Lung Cancer by Binding to EZH2 and Suppressing p53. Mol Ther Nucleic Acids. 2016;5(1):e385.
25. Xue J, Zhang F. LncRNA LINC00511 plays an oncogenic role in lung adenocarcinoma by regulating PDK2 expression via sponging miR-625-5p. Thorac Cancer. 2020;11(9):2570–9.
26. Zhang Y, Du W, Chen Z, Xiang C. Upregulation of PD-L1 by SPP1 mediates macrophage polarization and facilitates immune escape in lung adenocarcinoma. Exp Cell Res. 2017;359(2):449–57.
27. Li S, Yang R, Sun X, Maos S, Lu T, Wang Y, et al. Identification of SPP1 as a promising biomarker to predict clinical outcome of lung adenocarcinoma individuals. Gene. 2018;679:398–404.
28. Wang X, Zhang F, Yang X, Xue M, Li X, Gao Y, et al. Secreted Phospho-protein 1 (SPP1) Contributes to Second-Generation EGFR Tyrosine Kinase Inhibitor Resistance in Non-Small Cell Lung Cancer. Oncol Res. 2020;39(11):532.
29. Liu H, Wei S, Zhang L, Yuan C, Duan W, Yang Q. Secreted Phospho-protein 1 Promotes the Development of Small Cell Lung Cancer Cells by Inhibiting Autophagy and Apoptosis. Pathol Oncol Res. 2019;25(4):1487–95.
30. Luo J, Pan J, Jin Y, Li M, Chen M. MiR-195-5p Inhibits Proliferation and Induces Apoptosis of Non-Small Cell Lung Cancer Cells by Targeting CEP55. OncoTargets Ther. 2019;12:11465–74.
31. Bu L, Tian Y, Wen H, Jia W, Yang S. MiR-195-5p exerts tumor-suppressive functions in human lung cancer cells through targeting Tnr2. Acta Biochim Biophys Sin. 2021;53(2):189–200.
32. Long Z, Yang L. MiR-195-5p Suppresses Lung Cancer Cell Proliferation, Migration, and Invasion Via FOXK1. Technol Cancer Res Treat. 2020;19:3303383020922587.
33. Xin T, Li S, Zhang Y, Kamali X, Liu H, Jia T. circRNA Hsa_circ_0020850 Silences Represses the Development of Lung Adenocarcinoma via Regulating miR-195-5p/IRX2 Axis. Cancer Manag Res. 2020;12:10679–92.
34. Lu G, Li Y, Ma Y, Lu J, Chen Y, Jiang Q, et al. Long noncoding RNA LINC00511 contributes to breast cancer tumourigenesis and stemness by inducing the miR-185-3p/E2F1/Notch axis. Exp Clin Cancer Res. 2018;37(1):289.
35. Chen Z, Wu H, Zhang Z, Li G, Liu B. LINC00511 accelerated the process of gastric cancer by targeting miR-625-5p/NFIC axis. Cancer Cell Int. 2019;19:351.
37. Yu CL, Xu XL, Yuan F. LINC00511 is associated with the malignant status and promotes cell proliferation and motility in cervical cancer. Biosci Rep. 2019;39(9):BSR20190003.

38. Lin X, Wang S, Sun M, Zhang C, Wei C, Yang C, et al. miR-195-5p/NOTCH2-mediated EMT modulates IL-4 secretion in colorectal cancer to affect M2-like TAM polarization. J Hematol Oncol. 2019;12(1):20.

39. Yang R, Xing L, Zheng X, Sun Y, Wang X, Chen J. The circRNA circAGFG1 acts as a sponge of miR-195-5p to promote triple-negative breast cancer progression through regulating CCNE1 expression. Mol Cancer. 2019;18(1):4.

40. Liu X, Zhou Y, Ning YE, Gu H, Tong Y, Wang N. MiR-195-5p Inhibits Malignant Progression of Cervical Cancer by Targeting YAP1. OncoTargets Ther. 2020;13:931–44.

41. Li S, Guo W, Geng H, Wang C, Yang S, Xu X. LINC00511 exacerbated T-cell acute lymphoblastic leukemia via miR-195-5p/LRRK1 axis. Biosci Rep. 2020;40(5):BSR20193631.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.